TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16264054

Group type: EXPERIMENTAL
Intervention: Airway clearance techniques (chest wall percussion, vibration, huffing) during sputum induction
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard sputum induction procedure (without airway clearance techniques)
Number of subjects: 59
Study: 11916756

Group type: COMPARATOR
Intervention: 7 mg threonine x kg(‐1) x d(‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 15 mg threonine x kg(‐1) x d(‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 46 mg threonine x kg(‐1) x d(‐1)
Number of subjects: 15
Study: 9802665

Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM) machine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Professional physical therapy
Number of subjects: 80
Study: 7702053

Group type: EXPERIMENTAL
Intervention: Patients with IDWG > 3 kg (n = 138)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Patients with IDWG > 4.5% of dry weight (n = 151)
Number of subjects: 860

Group type: COMPARATOR
Intervention: Patients with IDWG < 2 kg (n = 378)
Number of subjects: 860

Group type: COMPARATOR
Intervention: Patients with IDWG < 3% of dry weight (n = 355)
Number of subjects: 860
Study: 2533210

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 33753

Group type: EXPERIMENTAL
Intervention: Alkaline artificial tear preparation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Current artificial tear preparations available in North America
Number of subjects: 20
Study: 30445507

Group type: EXPERIMENTAL
Intervention: Learn to Quit (LTQ) app combined with nicotine replacement therapy and technical coaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: NCI QuitGuide (QG) app combined with nicotine replacement therapy and technical coaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learn to Quit (LTQ) app
Number of subjects: 0
Study: 27121176

Group type: EXPERIMENTAL
Intervention: Alex laser at 3 ms pulse duration
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Alex laser at 5 ms pulse duration
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Alex laser at 10 ms pulse duration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 16
Study: 26018925

Group type: EXPERIMENTAL
Intervention: Hesperetin-7-O-rutinoside
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hesperetin-7-O-glucoside
Number of subjects: 0
Study: 23455591

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (Healthy Individuals)
Number of subjects: 79
Study: 21392641

Group type: EXPERIMENTAL
Intervention: Plasma biomarkers of inflammation (CRP, IL-6, WBC, ICAM-1)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: CFR measurement
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 268
Study: 18421257

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 0
Study: 17012959

Group type: EXPERIMENTAL
Intervention: Low-technology structured intervention including telephone and home visits, a teaching tool, digital scales, and a log/notebook filled out by the patients.
Number of subjects: 0
Study: 15117037

Group type: EXPERIMENTAL
Intervention: Stent placement (Crown Stent)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 42
Study: 10096452

Group type: EXPERIMENTAL
Intervention: Chlorphenylamine (CP), administered daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flurbiprofen (FB), administered daily for 7 days
Number of subjects: 0
Study: 7755942

Group type: EXPERIMENTAL
Intervention: 375 mg naproxen twice a day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2129651

Group type: EXPERIMENTAL
Intervention: 240 mg aminophylline i.v.
Number of subjects: 12

Group type: COMPARATOR
Intervention: 200 mg doxofylline i.v.
Number of subjects: 12

Group type: COMPARATOR
Intervention: 400 mg doxofylline i.v.
Number of subjects: 12
Study: 536100

Group type: EXPERIMENTAL
Intervention: Videotapes of a same-sex adult model eating at a reduced speed
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Videotapes of themselves eating at a reduced speed
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control condition (baseline eating behavior videotapes only)
Number of subjects: 18
Study: 31226996

Group type: EXPERIMENTAL
Intervention: SNAPPS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional case presentation
Number of subjects: 18
Study: 28126304

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/mitomycin-C/radiation therapy (Arm A)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/cisplatin/radiation therapy (Arm B)
Number of subjects: 282
Study: 25116574

Group type: EXPERIMENTAL
Intervention: Group E (bimonthly health worker‐initiated visits, counseling, and rewards for adherence)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Group E
Number of subjects: 460

Group type: COMPARATOR
Intervention: Group A (standard care services)
Number of subjects: 460
Study: 22413065

Group type: EXPERIMENTAL
Intervention: High protein diet (HP)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low protein diet (LP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Low calorie diet (LCD)
Number of subjects: 77
Study: 20649490

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17386123

Group type: EXPERIMENTAL
Intervention: Capecitabine and weekly paclitaxel
Number of subjects: 54
Study: 16033307

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) + sulfadoxine‐pyrimethamine (SP)
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) + sulfadoxine‐pyrimethamine (SP)
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) + artesunate (AS)
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Overall risk of repeat therapy due to any recurrent infection
Number of subjects: 2160
Study: 11981007

Group type: EXPERIMENTAL
Intervention: Ibandronate 2 mg IV monthly for 12 to 24 months
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Ibandronate 2 mg IV monthly
Number of subjects: 198
Study: 10207763

Group type: EXPERIMENTAL
Intervention: Decrease in dietary caffeine intake
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Increase in fluid intake
Number of subjects: 41
Study: 7530984

Group type: EXPERIMENTAL
Intervention: Tumour-infiltrating lymphocyte (TIL) infusion
Number of subjects: 9
Study: 2221611

Group type: EXPERIMENTAL
Intervention: Ceftazidime/clindamycin (CAZ/C)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Tobramycin/clindamycin (T/C)
Number of subjects: 94
Study: 7413691

Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (1.4% delta 9‐THC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 0
Study: 30880289

Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 111

Group type: COMPARATOR
Intervention: Air
Number of subjects: 111
Study: 27749225

Group type: EXPERIMENTAL
Intervention: Discontinuation of NSAIDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAID resumption upon symptom recurrence
Number of subjects: 0
Study: 26482662

Group type: COMPARATOR
Intervention: BoNT‐A (Cycle 1, n = 23)
Number of subjects: 41

Group type: COMPARATOR
Intervention: BoNT‐A (Cycle 2, n = 20)
Number of subjects: 41
Study: 24083884

Group type: EXPERIMENTAL
Intervention: Patient self-management (PSM)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 310
Study: 21237636

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Educational group programme (EGP)
Number of subjects: 320
Study: 19010349

Group type: EXPERIMENTAL
Intervention: FV Education (FVE)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Prostate Education (PE)
Number of subjects: 490
Study: 18257344

Group type: EXPERIMENTAL
Intervention: Slowly-releasing medication (intramuscular injection, made from Chinese herbs, administered at specific acupuncture points)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Western medicine (Rythmol, oral administration, 150 mg thrice daily)
Number of subjects: 238
Study: 17023280

Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine/fentanyl, 3 microg/mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.25% bupivacaine/fentanyl, 3 microg/mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 14514745

Group type: EXPERIMENTAL
Intervention: Protocolized anemia management with subcutaneous rHuEpo and intravenous iron
Number of subjects: 215

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Protocolized anemia management
Number of subjects: 215
Study: 10810685

Group type: EXPERIMENTAL
Intervention: Patient-controlled continuous infusion of lidocaine (2% solution, 2 cc/h continuous dose, 1 cc at 15-minute intervals for 72 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (24 patients undergoing acromioplasty without lidocaine analgesia)
Number of subjects: 24
Study: 9121819

Group type: EXPERIMENTAL
Intervention: Postoperative Pain Measure for Parents
Number of subjects: 110
Study: 1666917

Group type: EXPERIMENTAL
Intervention: Oral CBD (10 mg/kg/day = about 700 mg/day) for 6 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CBD discontinued after 6 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study: 7105820

Group type: EXPERIMENTAL
Intervention: 400 mg chlormezanone at night
Number of subjects: 44

Group type: COMPARATOR
Intervention: 5 mg diazepam 3-times daily for 4 weeks
Number of subjects: 44
Study: 31775877

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs) for Cryptosporidium spp.
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs) for Giardia duodenalis
Number of subjects: 295

Group type: COMPARATOR
Intervention: Multiplex PCR (reference test)
Number of subjects: 295
Study: 27584142

Group type: COMPARATOR
Intervention: Individualized exercises (G1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group exercises (G2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: No treatment (monitoring, G3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Raven colored matrices
Number of subjects: 24
Study: 26013912

Group type: EXPERIMENTAL
Intervention: Cocoa flavanol (CF) intake (450 mg CF) bi-daily for 14 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nutrient-matched, CF-free control drink bi-daily for 14 days
Number of subjects: 42
Study: 24092242

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paroxetine treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Between-group comparison for MMPI subscales paranoia and social introversion
Number of subjects: 60
Study: 21540476

Group type: EXPERIMENTAL
Intervention: PEX eyes
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fellow eyes
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal control eyes
Number of subjects: 42
Study: 19184761

Group type: EXPERIMENTAL
Intervention: Cereal bar for breakfast
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cereal bar as a mid-morning snack
Number of subjects: 32

Group type: COMPARATOR
Intervention: No breakfast
Number of subjects: 32

Group type: COMPARATOR
Intervention: No snack
Number of subjects: 32
Study: 17224808

Group type: EXPERIMENTAL
Intervention: Usual care plus patient choice of acupuncture, chiropractic, or massage therapy (choice)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 444
Study: 15363174

Group type: EXPERIMENTAL
Intervention: Apligraf
Number of subjects: 48

Group type: COMPARATOR
Intervention: Split-skin graft (SSG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dressing
Number of subjects: 48
Study: 11845944

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tretinoin microsphere gel 0.1%
Number of subjects: 40
Study: 9726554

Group type: EXPERIMENTAL
Intervention: Static two-point discrimination
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moving two-point discrimination
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Semmes-Weinstein monofilament testing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tinel's test
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Manual motor testing of abductor pollicis brevis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vibration test
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phalen's test
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Overall reliability of seven tests
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Examinations by hand surgeons and hand therapists
Number of subjects: 12
Study: 7831412

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 0
Study: 3207560

Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg single dose) with indomethacin pretreatment (25 mg four times daily for 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Indomethacin treatment alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Felodipine and felodipine plus indomethacin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Felodipine (10 mg single dose)
Number of subjects: 12
Study: 30827852

Group type: EXPERIMENTAL
Intervention: Low-energy extracorporeal shockwave therapy (0.05-0.20mJ/mm2, frequency of 4Hz, 1000 to 2000 shocks, once per week for 4 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo group (ESWT without energy)
Number of subjects: 45
Study: 27884801

Group type: EXPERIMENTAL
Intervention: Flexible duty hour policies
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard duty hour policies
Number of subjects: 154
Study: 25811486

Group type: EXPERIMENTAL
Intervention: Nurse-based case management (home visits and telephone calls for three years)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Nurse-based case management
Number of subjects: 340
Study: 24004232

Group type: COMPARATOR
Intervention: Butorphanol (0.4 mg/kg, SC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methadone (0.6 mg/kg, SC)
Number of subjects: 22
Study: 21385426

Group type: EXPERIMENTAL
Intervention: Group education during the first trimester of gestation on healthy hygiene-dietetic habits and the importance of an adequate iodine nutritional status
Number of subjects: 898
Study: 19397429

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% bupivacaine infiltration
Number of subjects: 40

Group type: COMPARATOR
Intervention: No infiltration (control group)
Number of subjects: 40
Study: 17239710

Group type: EXPERIMENTAL
Intervention: Anterior fat pad (AFP) maintenance
Number of subjects: 180

Group type: COMPARATOR
Intervention: AFP removal
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: AFP maintenance
Number of subjects: 180
Study: 15129200

Group type: EXPERIMENTAL
Intervention: Mulligan's Mobilization With Movement (MWM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18

Group type: COMPARATOR
Intervention: No-substance control
Number of subjects: 18
Study: 11968135

Group type: EXPERIMENTAL
Intervention: Magnetic resonance microscopy imaging at 11.7 T
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Histological slices
Number of subjects: 4
Study: 10199880

Group type: EXPERIMENTAL
Intervention: Intranasal butorphanol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 8564589

Group type: EXPERIMENTAL
Intervention: Educational videotapes mailed to study group
Number of subjects: 4246

Group type: COMPARATOR
Intervention: Control group (no educational materials)
Number of subjects: 4246

Group type: EXPERIMENTAL
Intervention: Survey respondents from study group
Number of subjects: 4246
Study: 1972861

Group type: EXPERIMENTAL
Intervention: xamoterol, 200 mg twice a day
Number of subjects: 51

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study: 93486

Group type: EXPERIMENTAL
Intervention: Individual speech therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intervention from untrained volunteers
Number of subjects: 13
Study: 31790913

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 199
Study: 31045830

Group type: EXPERIMENTAL
Intervention: Soshiho-tang (SSHT) administered 3 times a day for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo administered 3 times a day for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soshiho-tang (SSHT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28671102

Group type: EXPERIMENTAL
Intervention: Pentoxifylline intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scalping forehead flap technique
Number of subjects: 0
Study: 26027102

Group type: EXPERIMENTAL
Intervention: Calcium ionophore A23187-activation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 2
Study: 22928803

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type-A (BoNT-A) injection
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Strength training (10 weeks)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Strength training and BoNT-A (combined intervention)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Goal Attainment Scale (GAS) assessment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 15
Study: 21342644

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed concurrent chemoradiotherapy (Paclitaxel liposme 135 mg/m²-175 mg/m², d1 and cisplatin 70 mg/m²-80 mg/m², d2, 3 weeks repeat)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sequential radiotherapy (4-6 cycles of chemotherapy followed by one cycle of radiotherapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed concurrent chemoradiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sequential radiotherapy
Number of subjects: 60
Study: 19688338

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily (n = 230)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Insulin glargine (n = 232)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Placebo (n = 114)
Number of subjects: 581
Study: 17763372

Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 3049

Group type: EXPERIMENTAL
Intervention: pamidronate
Number of subjects: 3049

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3049
Study: 15108949

Group type: EXPERIMENTAL
Intervention: Arm massage by significant others
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no arm massage)
Number of subjects: 59
Study: 11211642

Group type: EXPERIMENTAL
Intervention: Televised antimarijuana campaigns (3 campaigns total; 2 in one county, 1 in comparison community)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control community (1 campaign)
Number of subjects: 100
Study: 9377538

Group type: EXPERIMENTAL
Intervention: Modafinil (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-Amphetamine (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8467105

Group type: EXPERIMENTAL
Intervention: Chronically increased vitamin intake for 8 weeks
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 498
Study: 3516092

Group type: EXPERIMENTAL
Intervention: tibalosine 150 mg daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: tibalosine plus atenolol 100 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: tibalosine plus chlorthalidone 50 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: tibalosine
Number of subjects: 26
Study: 31502387

Group type: EXPERIMENTAL
Intervention: Horse riding simulator (HRS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Corner seat placement (Control)
Number of subjects: 24
Study: 31053348

Group type: EXPERIMENTAL
Intervention: Cefuroxime administered before skin incision
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cefuroxime administered after cutting the umbilical cord
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 42
Study: 27890592

Group type: EXPERIMENTAL
Intervention: Fabuless® emulsion (FEM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dairy emulsion with dairy emulsifier (DEDE)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dairy emulsion with soy lecithin emulsifier (DESE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dairy control (DCON)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Palmolein emulsion with dairy emulsifier (PEDE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Palmolein control (PCON)
Number of subjects: 18
Study: 25838311

Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite (NaNO2) at 50 μg/kg/min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite (NaNO2) at 10 μg/kg/min
Number of subjects: 25
Study: 23785676

Group type: EXPERIMENTAL
Intervention: Subcutaneous specific immunotherapy in 57 allergic patients (70.3%)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Intranasal glucocorticosteroids in 47 patients with rhinitis medicamentosa (37.9%)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 124
Study: 20979591

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19126110

Group type: EXPERIMENTAL
Intervention: Probing pressure of 0.15 N
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Probing pressure of 0.25 N
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Probing pressure (both 0.15 N and 0.25 N)
Number of subjects: 17